An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
Crossref DOI link: https://doi.org/10.1158/1078-0432.CCR-18-0204
Published Online: 2018-07-01
Published Print: 2018-07-01
Update policy: https://doi.org/10.1158/crossmark_policy
Pulliam, Nicholas
Fang, Fang
Ozes, Ali R.
Tang, Jessica
Adewuyi, Adeoluwa
Keer, Harold
Lyons, John
Baylin, Stephen B.
Matei, Daniela
Nakshatri, Harikrishna
Rassool, Feyruz V.
Miller, Kathy D.
Nephew, Kenneth P.
Funding for this research was provided by:
NIH (R01-CA182832)